-
市场
-
产品
-
资讯
-
Moo社区
-
课堂
-
查看更多
-
功能介绍
-
费用费用透明,无最低余额限制
投资选择、功能介绍、费用相关信息由Moomoo Financial Inc.提供
- English
- 中文繁體
- 中文简体
- 深色
- 浅色
Marijuana Research Focuses Strictly On Potential Harms From THC, NCCIH Director Says
Marijuana Research Focuses Strictly On Potential Harms From THC, NCCIH Director Says
Director of the National Center for Complementary and Integrative Health (NCCIH) Helene Langevin recently pointed out that the abundance of federally funded research on cannabis has "narrowly focused on the potential harms" of THC.
"There is growing interest among health care providers and the public in understanding the potential therapeutic uses of cannabis-related products," Langevin said. "But that interest must be matched by research that can deepen our knowledge and inform health decisions."
The fact that marijuana still remains a Schedule I drug under the Controlled Substances Act (CSA) is the main barrier that's hindered studies, Langevin pointed out. "Research on cannabinoids is fraught with hurdles," she continued.
In addition, NCCIH recently published a "Request for Information" (RFI), soliciting feedback from the scientific community "about its interest in and barriers to research on the health effects of cannabis and its constituents," Marijuana Moment first reported.
What Would Be The Solution To Avoid Cannabis Research Obstacles?
"A key step in successfully generating more scientific evidence around the potential clinical uses of cannabis products is to identify barriers to conducting research and subsequently develop approaches that can help overcome them," Langevin said. "The RFI responses we receive will help broaden our understanding of the research infrastructure needed to foster rigorous studies and identify areas of interest within the field."
Langevin said she views NCCIH's "ongoing work in cannabinoids research as a natural extension of our broader effort to advance the scientific understanding of whole person health."
More Research To Stop Public Health Crisis
In addition, the National Institutes of Health (NIH) recently released a Notice of Special Interest (NOSI) to promote "mechanistic research" into minor cannabinoids like CBG, CBN, and delta-8 THC.
"These activities are timely, especially given the potential role of cannabinoids in managing pain," Langevin said. "The overreliance on opioids has created a public health crisis and incalculable losses across the nation. Driving research that could yield new, potentially safer tools that meet the needs of people who suffer from chronic pain is an essential step in addressing the problem at its root."
Recently, Khiron Life Sciences Corp. (OTCQX:KHRNF) (TSXV: KHRN.V) published in the international peer-reviewed journal Frontiers in Pain Research the results of its first clinical study on the use of medical cannabis prescribed to Colombian patients in treating chronic pain. This is the first published clinical evidence on the effectiveness and safety of Khiron's THC and CBD oil-based cannabis formulations, the two most prescribed products at Khiron's Zerenia Clinics in Colombia.
Photo: Courtesy Of Girl with red hat On Unsplash
Director of the National Center for Complementary and Integrative Health (NCCIH) Helene Langevin recently pointed out that the abundance of federally funded research on cannabis has "narrowly focused on the potential harms" of THC.
"There is growing interest among health care providers and the public in understanding the potential therapeutic uses of cannabis-related products," Langevin said. "But that interest must be matched by research that can deepen our knowledge and inform health decisions."
国家补充与综合健康中心的董事海琳·朗之万 最近指出,联邦政府资助的大量大麻研究“狭隘地集中在四氢大麻酚的潜在危害上”.
朗之万说:“卫生保健提供者和公众对了解大麻相关产品的潜在治疗用途越来越感兴趣。”但这种兴趣必须与能够加深我们的知识并为健康决策提供信息的研究相匹配。
The fact that marijuana still remains a Schedule I drug under the Controlled Substances Act (CSA) is the main barrier that's hindered studies, Langevin pointed out. "Research on cannabinoids is fraught with hurdles," she continued.
朗之万指出,根据受控物质法案(CSA),大麻仍然是第一类药物,这一事实是阻碍研究的主要障碍。“对大麻素的研究充满了障碍她继续说道。
In addition, NCCIH recently published a "Request for Information" (RFI), soliciting feedback from the scientific community "about its interest in and barriers to research on the health effects of cannabis and its constituents," Marijuana Moment first reported.
此外,NCCIH最近发表了一份“索取资料(RFI),正在征求科学界的反馈意见,“关于他们对大麻及其成分对健康影响的研究的兴趣和障碍”,大麻时刻首次报道。
What Would Be The Solution To Avoid Cannabis Research Obstacles?
什么是避免大麻研究障碍的解决方案?
"A key step in successfully generating more scientific evidence around the potential clinical uses of cannabis products is to identify barriers to conducting research and subsequently develop approaches that can help overcome them," Langevin said. "The RFI responses we receive will help broaden our understanding of the research infrastructure needed to foster rigorous studies and identify areas of interest within the field."
要成功地围绕大麻产品的潜在临床用途产生更多科学证据,关键的一步是找出进行研究的障碍,并随后开发有助于克服这些障碍的方法。朗之万说。我们收到的RFI答复将有助于扩大我们对促进严格研究和确定该领域感兴趣领域所需的研究基础设施的了解。“
Langevin said she views NCCIH's "ongoing work in cannabinoids research as a natural extension of our broader effort to advance the scientific understanding of whole person health."
朗之万说,她认为NCCIH的正在进行的大麻素研究工作是我们推进对整体健康的科学理解的更广泛努力的自然延伸。“
More Research To Stop Public Health Crisis
更多研究遏制公共卫生危机
In addition, the National Institutes of Health (NIH) recently released a Notice of Special Interest (NOSI) to promote "mechanistic research" into minor cannabinoids like CBG, CBN, and delta-8 THC.
此外,美国国立卫生研究院(NIH)最近发布了一个特别利息通知书(NOSI)推动“机械论研究”少量大麻素,如CBG、CBN和Delta-8 THC.
"These activities are timely, especially given the potential role of cannabinoids in managing pain," Langevin said. "The overreliance on opioids has created a public health crisis and incalculable losses across the nation. Driving research that could yield new, potentially safer tools that meet the needs of people who suffer from chronic pain is an essential step in addressing the problem at its root."
“这些活动是及时的,特别是考虑到大麻类药物在止痛方面的潜在作用,”朗之万说。对阿片类药物的过度依赖在全国范围内造成了公共健康危机和不可估量的损失。推动研究,可能产生新的、潜在更安全的工具,满足慢性疼痛患者的需求,是从根本上解决问题的关键一步。
Recently, Khiron Life Sciences Corp. (OTCQX:KHRNF) (TSXV: KHRN.V) published in the international peer-reviewed journal Frontiers in Pain Research the results of its first clinical study on the use of medical cannabis prescribed to Colombian patients in treating chronic pain. This is the first published clinical evidence on the effectiveness and safety of Khiron's THC and CBD oil-based cannabis formulations, the two most prescribed products at Khiron's Zerenia Clinics in Colombia.
最近, 科隆生命科学公司。(OTCQX:KHRNF)(TSXV:KHRN.V)发表在国际同行评议中疼痛研究前沿杂志该中心首次对哥伦比亚患者使用医用大麻治疗慢性疼痛进行了临床研究。这是首次发表的关于Khron的THC和CBD油基大麻制剂有效性和安全性的临床证据,这两种产品是Khron在哥伦比亚的Zerenia诊所最常用的处方产品。
Photo: Courtesy Of Girl with red hat On Unsplash
图片:Unspash上戴红帽子的女孩提供
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国,moomoo上的投资产品和服务由Moomoo Financial Inc.提供,一家受美国证券交易委员会(SEC)监管的持牌主体。 Moomoo Financial Inc.是金融业监管局(FINRA)和证券投资者保护公司(SIPC)的成员。
在新加坡,moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供,该公司受新加坡金融管理局(MAS)监管(牌照号码︰CMS101000) ,持有资本市场服务牌照 (CMS) ,持有财务顾问豁免(Exempt Financial Adviser)资质。本内容未经新加坡金融管理局的审查。
在澳大利亚,moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供,该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构(AFSL No. 224663)。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件,这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大,通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供,并受加拿大投资监管机构(CIRO)监管。
在马来西亚,moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供,该公司受马来西亚证券监督委员会(SC)监管(牌照号码︰eCMSL/A0397/2024) ,持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
风险及免责提示
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国,moomoo上的投资产品和服务由Moomoo Financial Inc.提供,一家受美国证券交易委员会(SEC)监管的持牌主体。 Moomoo Financial Inc.是金融业监管局(FINRA)和证券投资者保护公司(SIPC)的成员。
在新加坡,moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供,该公司受新加坡金融管理局(MAS)监管(牌照号码︰CMS101000) ,持有资本市场服务牌照 (CMS) ,持有财务顾问豁免(Exempt Financial Adviser)资质。本内容未经新加坡金融管理局的审查。
在澳大利亚,moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供,该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构(AFSL No. 224663)。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件,这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大,通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供,并受加拿大投资监管机构(CIRO)监管。
在马来西亚,moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供,该公司受马来西亚证券监督委员会(SC)监管(牌照号码︰eCMSL/A0397/2024) ,持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用浏览器的分享功能,分享给你的好友吧